Why Eli Lilly Stock Trounced the Market on Tuesday

There's nothing like a successful clinical trial of a high-potential medicine to blast a pharmaceutical company's stock price higher. That was the dynamic behind Eli Lilly's (NYSE: LLY) nearly 6% gain on Tuesday, which easily beat the S&P 500's (SNPINDEX: ^GSPC) 0.4% bump higher. Well before market open, Eli Lilly announced the top-line results from a phase 3 trial of its orforglipron, an orally administered GLP-1 weight loss drug akin to its Zepbound and healthcare sector rival Novo Nordisk's Wegovy. The company said that orforglipron met all of its primary, and the key secondary, endpoints. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool